Certest Pharma

✨Let’s start the Tuesday with our section of #DeliveringScience with: Achieving Targeted Delivery of Therapeutic Oligonucleotides: The Role of Peptide Conjugation. At Certest Pharma, we’re pioneering the delivery of nucleic acids using LNPs and ionizable lipids. One exciting breakthrough is targeting therapeutic oligonucleotides to specific organs using active targeting. 👉🏻What is Active Targeting? Active targeting modifies therapeutic agents to bind to specific cells. By conjugating oligonucleotides to peptides, we can direct them precisely to their targets, minimizing off-target effects and boosting efficacy. 🧬 👉🏻Peptide Conjugation: Precision in Action Peptides, short amino acid chains, can be designed to bind to specific cell receptors. When linked to oligonucleotides, they act as homing devices, ensuring delivery to the right place. 🎯 👉🏻Why It Matters This approach is promising for cancer therapy, targeting tumor markers, and genetic disorder treatments, correcting genes in specific organs. 🌟 At Certest Pharma, we’re committed to advancing nucleic acid delivery with innovative solutions like peptide conjugation. Stay tuned for more updates! #CertestPharma #Targeting #OligonucleotideTherapeutics

🌎Today, on World Hepatitis Day, we at Certest Pharma reaffirm our commitment to combating hepatitis through innovative RNA-based therapies. Hepatitis remains a global health challenge, affecting millions of lives. By harnessing the power of RNA and advanced delivery technologies, we are committed to targeted therapies that offer hope for effective and lasting solutions. 🤲🏻Join us in raising awareness and supporting the fight against hepatitis. Together, we can make a difference. #WorldHepatitisDay #CertestPharma #RNATherapies #HealthcareInnovation

Meet Pedro R. Villuendas Piqueras Oligotherapeutics Manager at Certest Pharma. 👨🏻🔬Inorganic Chemistry at the University of Zaragoza. Then, he moved to the UK to pursue his Ph.D. of Chemistry. In 2012, Pedro joined The Institute of Chemical Synthesis and Homogeneous Catalysis in Zaragoza, contributing to 33 publications and a book chapter across various fields including homogeneous and heterogeneous catalysis, organic and inorganic chemistry. Pedro began his journey at Certest Biotec in Zaragoza as Head of the OligoSynthesis Department, where he oversaw the manufacturing of oligos, primarily for diagnostic purposes. Since January 2024, he has been serving as the Oligotherapeutics Manager at Certest Pharma. 🤝🏻Pedro and his team are involved in numerous projects focused on the screening and discovery of new oligonucleotides. Their work emphasizes delivery using a variety of directing groups such as lipids and peptides, developing new synthetic processes to produce high purity oligos in multigram quantities, and creating analytical procedures to ensure the highest purity throughout the synthetic process. ⚽Outside of his professional life, Pedro is passionate about sports, particularly football and handball, and enjoys hiking. #CerTeamPharma

🔬#DeliveringScience: Understanding the Processes in Therapeutic Oligonucleotide Synthesis At Certest Pharma, we pride ourselves on our expertise in the synthesis of therapeutic oligonucleotides. This intricate process can be divided into two main stages: upstream and downstream. 🔹Upstream Process: it involves the initial steps of oligonucleotide synthesis, including the design and chemical synthesis of the oligonucleotide sequences. This stage is crucial as it sets the foundation for the entire process. Precision and accuracy are paramount here, and at Certest Pharma, we ensure that every sequence is meticulously crafted to meet the highest standards. 🔹Downstream Process: it encompasses the purification, characterization, and quality control of the synthesized oligonucleotides. This stage is equally critical as it ensures the final product’s purity, potency, and safety. Our advanced purification techniques and rigorous quality control measures guarantee that our oligonucleotides are of the highest quality. 🔎Where Control is Key: While both stages are essential, the downstream process requires heightened control to ensure the final product’s integrity. At Certest Pharma, we excel in this area, employing state-of-the-art technologies and stringent protocols to maintain the highest level of control and quality assurance. By mastering both the upstream and downstream processes, Certest Pharma delivers therapeutic oligonucleotides that meet the most demanding standards of the pharmaceutical industry. Our commitment to excellence ensures that we provide our clients with products they can trust.   #CertestPharma #Oligosynthesis #Upstream #Downstream #DrugDelivery

🌐 World Brain Day: Advancing Brain Health with RNA-Based Therapies 🧠 On this World Brain Day, Certest Pharma proudly joins the global community in raising awareness about brain health. At Certest Pharma, we are committed to pioneering innovative treatments that harness the power of RNA-based therapies using advanced drug delivery systems with Lipid Nanoparticles (LNPs) and ionizable lipids. The brain is a complex and vital organ, responsible for our thoughts, memories, and actions. However, it is also susceptible to various debilitating diseases. Among the most common and challenging brain diseases are: 👉🏻Alzheimer's Disease: A progressive disorder that affects memory and cognitive function. 👉🏻Parkinson's Disease: A neurodegenerative disorder that impacts movement and coordination. 👉🏻Stroke: A sudden interruption in the blood supply to the brain, leading to significant neurological damage. At Certest Pharma, we believe that RNA-based therapies represent a promising frontier in the fight against these devastating conditions. Our cutting-edge research focuses on developing targeted treatments that can effectively cross the blood-brain barrier, offering hope for improved outcomes and enhanced quality of life for patients. On this special day, we reaffirm our dedication to advancing brain health and our commitment to scientific excellence. Together, let's work towards a future where neurological diseases are better understood, better treated, and ultimately, overcome. #WorldBrainDay #BrainHealth #RNATherapy #DrugDelivery #CertestPharma

🔬 Unlocking the Power of Oligonucleotide Therapeutics: A Peek into Our Services. 🌐 Screening and Discovery: Our department is dedicated to innovation. Our team delves deeply into the realm of oligonucleotides, exploring novel sequences and identifying potential therapeutic candidates. 🔍 Process Development: We optimize the production process for oligonucleotides, meticulously fine-tuning each step to achieve maximum yield and purity. From chemical synthesis to purification, we ensure that your therapeutic candidates are robust and reproducible. 📊 Analysis Development: Our analytical team validates and characterizes oligonucleotides, utilizing cutting-edge techniques to assess their stability, degradability and more. Rigorous analysis guarantees that your therapeutic candidates are not only effective but also reliable. From Lead Optimization to SOP: Our services encompass the entire journey. We support you at every stage, ensuring seamless transitions and robust outcomes. Our commitment to standard operating procedures (SOPs) underscores our dedication to quality. 🎯 Targeted Delivery Solutions: Our expertise extends beyond the laboratory. We are pioneers in delivery strategies, proficient in both passive and active targeting. Whether utilizing lipid nanoparticles (LNPs) or peptide conjugation, we excel in delivering precise solutions. Connect with Certest to Learn More! Curious about how our oligonucleotide services can transform your therapeutic pipeline? Drop a comment or send us a message. Together, we can revolutionize healthcare, one nucleotide at a time.

🚀 #DeliveringScience: Exploring Oligonucleotide-Based Therapies At Certest Pharma, we're passionate about advancing biotechnological innovations. Oligonucleotide-based therapies are at the forefront of modern medicine, offering precise and targeted treatments for various genetic disorders. Let's delve into the different types: 🔹Antisense Oligonucleotides (ASOs): These bind to RNA molecules to modulate gene expression, offering therapeutic potential in conditions like spinal muscular atrophy. 🔹Small Interfering RNAs (siRNAs): siRNAs degrade specific mRNA molecules, effectively silencing genes involved in diseases like cancer and viral infections. 🔹Aptamers: Aptamers are short, single-stranded DNA or RNA molecules that bind to specific targets, such as proteins, with high affinity, serving as excellent therapeutic and diagnostic tools. 🔹Locked Nucleic Acids (LNAs): LNAs enhance the stability and binding affinity of oligonucleotides, improving their efficacy and safety in gene silencing applications. The advantages of these therapies include high specificity, the ability to target previously "undruggable" genes, and a relatively rapid development timeline compared to traditional small-molecule drugs. As we continue to innovate and improve these technologies, we move closer to tailored treatments that can change lives. 💡Stay tuned for more updates from Certest Pharma as we push the boundaries of science! #CertestPharma #Oligonucleotides #Biotech #GeneTherapy #Innovation

🔬 Let’s start the week with a new chapter of #MondayScienceReads! Got 5 minutes to disconnect from your routine and dive into the world of #Biotech? Check out this article on innovative strategies for designing gapmer antisense oligonucleotides to target the COL6A3 gene mutation in Ullrich congenital muscular dystrophy. Discover how novel ASO designs improve specificity and provide insights into their silencing effects, offering promising therapeutic implications for precision gene silencing. 📑Read the article below.   #CertestPharma #RNAtherapy #Oligonucleotides #BiotechInnovation

🎬 Today, we're excited to share a 20-second video showcasing a glimpse of our RNA Design department at Certest Pharma. At Certest Pharma, we are dedicated to the effective design of various RNA molecules, including mRNA, saRNA, circRNA, and more. Our meticulous process involves studying and modifying the ribonucleic acid molecule to achieve optimization of codons, UTRs (featuring our proprietary UTRs), and polyA tail. Additionally, our bioinformatics efforts enable us to perform simulations, protein design, and enhance the overall efficiency of our department. 👉🏻 Check out the video to see our cutting-edge work in action!

🔬🌐 Bioinformatics is transforming biotechnology, especially in designing RNA for therapeutic applications. By combining biology, computer science, and information technology, bioinformatics enables the analysis of complex biological data. This capability is crucial for developing precise RNA-based therapies, such as mRNA vaccines and RNA interference (RNAi) treatments, which are making strides in combating infectious diseases, genetic disorders, and cancer. Here are four key reasons why bioinformatics is vital in this field: 🔹Data Analysis: Bioinformatics allows researchers to process and interpret vast amounts of biological data, leading to better understanding and insights into disease mechanisms. 🔹Precision Design: Advanced bioinformatics tools enable the accurate design of RNA sequences, ensuring their effectiveness and safety in targeting specific genes or proteins. 🔹Predictive Modeling: Bioinformatics provides predictive models that help foresee the behaviour of RNA molecules in the body, enhancing the development of effective therapies. 🔹Efficiency: By automating and streamlining research processes, bioinformatics significantly reduces the time and cost associated with drug development. At Certest Pharma, we leverage these capabilities to design innovative RNA therapies that improve patient outcomes and advance global health. #CertestPharma #Bioinformatics #Biotechnology #RNATherapeutics